Citigroup Lowers ResMed Price Target

Analysts cite $340 price target for medical equipment provider's stock

Apr. 11, 2026 at 11:08am

Got story updates? Submit your updates here. ›

A high-contrast, macro-level view of the internal gears, circuits, and mechanical components of a ResMed medical device, conveying the industrial power and precision of the company's respiratory care technology.An extreme close-up of the inner workings of a ResMed medical device highlights the complex engineering behind the company's respiratory care solutions.San Diego Today

Citigroup analysts have lowered their price target for ResMed (NYSE:RMD) stock from $345 to $340, while maintaining a 'buy' rating on the medical equipment provider's shares. The new target price still represents a potential upside of 48.45% from the stock's current trading price.

Why it matters

ResMed is a leading global provider of sleep apnea and respiratory care devices. Analyst price targets and ratings can influence investor sentiment and trading activity around the stock.

The details

In a report released on Thursday, Citigroup analysts cited the new $340 price target for ResMed, down from their previous target of $345. The firm currently has a 'buy' rating on the stock. Citigroup's updated price target suggests a potential upside of 48.45% from ResMed's current trading price.

  • The report was released on Thursday, April 11, 2026.

The players

Citigroup

A global investment bank and financial services corporation.

ResMed (NYSE:RMD)

A medical device company that develops, manufactures and distributes products for the treatment of sleep-disordered breathing and other respiratory conditions.

Got photos? Submit your photos here. ›

The takeaway

This price target adjustment by a major investment bank reflects the ongoing importance of ResMed's medical devices and cloud-connected respiratory care solutions in the global healthcare market.